Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Arrowhead Pharmaceuticals, Inc.”

89 pharma patents match "Arrowhead Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 89
Index total 30,257
Page 3 / 4

Quick answer

This filtered view shows 89 pharmaceutical patents matching "Arrowhead Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

89 results for “Arrowhead Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 10308941

    Compositions and methods for inhibiting gene expression of factor XII

    Arrowhead Pharmaceuticals, Inc. · Granted Jun 4, 2019 · Expires May 30, 2039

    granted

  2. US 10294474

    Targeting ligands

    Arrowhead Pharmaceuticals, Inc. · Granted May 21, 2019 · Expires May 16, 2039

    granted

  3. US 10287582

    Organic compositions to treat HSF1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted May 14, 2019 · Expires May 9, 2039

    granted

  4. US 10273482

    dsRNA for treating viral infection

    Arrowhead Pharmaceuticals, Inc. · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  5. US 10246709

    Targeting ligands for therapeutic compounds

    Arrowhead Pharmaceuticals, Inc. · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted

  6. US 10240153

    Organic compositions to treat APOC3-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Mar 26, 2019 · Expires Mar 21, 2039

    granted

  7. US 10138483

    Transferrin/transferrin receptor-mediated siRNA delivery

    Arrowhead Pharmaceuticals, Inc. · Granted Nov 27, 2018 · Expires Nov 22, 2038

    granted

  8. US 10130651

    RNAi Therapy for Hepatitis B Virus Infection

    Arrowhead Pharmaceuticals, Inc. · Granted Nov 20, 2018 · Expires Nov 15, 2038

    granted

  9. US 10081811

    Organic compositions to treat Beta-ENaC-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Sep 25, 2018 · Expires Sep 20, 2038

    granted

  10. US 10047361

    Disulfide-containing alkyne linking agents

    Arrowhead Pharmaceuticals, Inc. · Granted Aug 14, 2018 · Expires Aug 9, 2038

    granted

  11. US 10023862

    Organic compositions to treat beta-catenin-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  12. US 10022456

    Reversibly masked polymers

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 17, 2018 · Expires Jul 12, 2038

    granted

  13. US 10006025

    Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

    Arrowhead Pharmaceuticals, Inc. · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted

  14. US 10005815

    Biologically cleavable tetrapeptide linking agents

    Arrowhead Pharmaceuticals, Inc. · Granted Jun 26, 2018 · Expires Jun 21, 2038

    granted

  15. US 9976141

    Compositions and methods for inhibiting gene expression of Hif2alpha

    Arrowhead Pharmaceuticals, Inc. · Granted May 22, 2018 · Expires May 17, 2038

    granted

  16. US 9938531

    Compositions and methods for inhibiting expression of RRM2 genes

    Arrowhead Pharmaceuticals, Inc. · Granted Apr 10, 2018 · Expires Apr 5, 2038

    granted

  17. US 9932584

    Interfering RNA delivery system and uses thereof

    Arrowhead Pharmaceuticals, Inc. · Granted Apr 3, 2018 · Expires Mar 29, 2038

    granted

  18. US 9914927

    RNAi inhibition of alpha-ENaC expression

    Arrowhead Pharmaceuticals, Inc. · Granted Mar 13, 2018 · Expires Mar 8, 2038

    granted

  19. US 9868949

    Organic compositions to treat EPAS1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Jan 16, 2018 · Expires Jan 11, 2038

    granted

  20. US 9803201

    Disulfide-containing alkyne linking agents

    Arrowhead Pharmaceuticals, Inc. · Granted Oct 31, 2017 · Expires Oct 26, 2037

    granted

  21. US 9803205

    Compositions and methods for inhibiting gene expression of factor XII

    Arrowhead Pharmaceuticals, Inc. · Granted Oct 31, 2017 · Expires Oct 26, 2037

    granted

  22. US 9795684

    Interfering RNA delivery system and uses thereof

    Arrowhead Pharmaceuticals, Inc. · Granted Oct 24, 2017 · Expires Oct 19, 2037

    granted

  23. US 9796756

    Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

    Arrowhead Pharmaceuticals, Inc. · Granted Oct 24, 2017 · Expires Oct 19, 2037

    granted

  24. US 9765340

    RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders

    Arrowhead Pharmaceuticals, Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.